Merger & Acquisition
Reid Connolly talks the benefits of buying San Francisco-based firm Giant.
Payer Sciences is a health marketing agency that uses data and analytics to gather insights about payer behavior.
Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.
U.S. deals through the end of March increased 366% compared with last year.
Dohmen will continue to operate under its brand and retain its leadership team.
The agency M&A market is changing as the big ad groups have been "distracted" by internal restructuring and new acquirers are emerging.
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
This time around the M&A moves will be much bigger in scope, promising to reconfigure the complex and fragile healthcare payer/provider/patient ecosystem.
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info
Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's
WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.
Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies